Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Novacyt ( (FR:ALNOV) ) is now available.
Novacyt has reported its latest monthly activity under a French-law governed liquidity agreement with Invest Securities, disclosing that in January 2026 the broker bought 11,018 ordinary shares and sold 16,569, leaving 113,915 shares held in treasury. The company confirmed that it has 70,626,248 ordinary shares in issue, a figure shareholders can use for regulatory threshold calculations under French law, while reiterating that it is outside the UK’s standard transparency regime; the update underlines the ongoing use of the liquidity facility, authorised by shareholders to stabilise trading in the stock through limited buybacks that may support share liquidity without conferring voting or dividend rights on treasury holdings.
More about Novacyt
Novacyt S.A. is an international molecular diagnostics company focused on genomic medicine, developing, manufacturing and commercialising molecular assays and instrumentation that deliver end-to-end workflows from sample to result. Its activities span human, animal and environmental health across three segments: clinical in vitro diagnostics in reproductive health, precision medicine and infectious diseases; DNA sample preparation and rapid PCR instrumentation, including its Ranger technology and genesig qPCR platforms; and research-use-only services such as bespoke qPCR assay design and next-generation sequencing support for global health and life sciences customers. Headquartered in Le Vésinet, France, with additional offices in the UK, Singapore, the US and Canada, Novacyt markets its products in more than 65 countries and is dual-listed on AIM in London and Euronext Growth in Paris.
For an in-depth examination of ALNOV stock, go to TipRanks’ Overview page.